Skip to content

State at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
-$3.05M-25.5%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
-$46K-333%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit.

The official record: Zymeworks’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's state.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's state?
Zymeworks (ZYME) reported state of $0 in Q4 2025.
What does state mean?
The change in deferred tax assets and liabilities specifically attributable to state and local tax jurisdictions. This reflects the future tax impact of temporary differences between financial reporting and state tax regulations. It is used to reconcile the effective tax rate and assess long-term state tax liabilities.